RA-ILD patients treated with ABA may face a higher risk of mortality and mechanical ventilation compared to those receiving TNFis, especially among specific subgroups such as younger patients, those with cardiovascular risk factors, and ACPA-positive individuals [32]. This evidence concerns the gene PRTN3 and interstitial lung disease.